Effects of Phthalates on Androgen Receptor Regulation Associated with Castration-Resistant Prostate Cancer Development
Abstract
Prostate cancer is one of the leading causes of death for men in the United States. Initially, prostate cancer patients are treated with androgen deprivation therapy. This treatment is usually successful at first; however, prostate cancer can recur years later as castration resistant prostate cancer (CRPC). CRPC is much more aggressive and is frequently lethal. Despite the immense clinical significance of CRPC, little is known about the molecular mechanisms that cause prostate cancer to become castration-resistant. We have found that the RNA helicase DDX3 plays a critical role in translational control of the androgen receptor (AR) in CRPC, highlighting a new mechanism by which prostate cancer becomes castration resistant. Future efforts will be dedicated to determining if DDX3-dependent translational control plays a role in phthalate-triggered reduction of AR in prostate cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2018
- Accession Number
- AD1093751
Entities
People
- Sarah Neuman
Organizations
- University of Wisconsin System